Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 553

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review

Open access
Pang, Junxiong, Wang, Min Xian, Ang, Ian Yi Han, Tan, Sharon Hui Xuan, Lewis, Ruth Frances, Chen, Jacinta I-Pei, Gutierrez, Ramona A, Gwee, Sylvia Xiao Wei, Chua, Pearleen Ee Yong, Yang, Qian, Ng, Xian Yi, Yap, Rowena K.S., Tan, Hao Yi, Teo, Yik Ying, Tan, Chorh Chuan, Cook, Alex R., Yap, Jason Chin-Huat, Hsu, Li Yang·2020·Journal of Clinical Medicine

Abstract

Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development. A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Supplementary strategies through Google Search and personal communications were used. A total of 27 studies fulfilled the criteria for review. Several laboratory protocols for confirmation of suspected 2019-nCoV cases using real-time reverse transcription polymerase chain reaction (RT-PCR) have been published. A commercial RT-PCR kit developed by the Beijing Genomic Institute is currently widely used in China and likely in Asia. However, serological assays as well as point-of-care testing kits have not been developed but are likely in the near future. Several vaccine candidates are in the pipeline. The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate. A number of novel compounds as well as therapeutics licensed for other conditions appear to have in vitro efficacy against the 2019-nCoV. Some are being tested in clinical trials against MERS-CoV and SARS-CoV, while others have been listed for clinical trials against 2019-nCoV. However, there are currently no effective specific antivirals or drug combinations supported by high-level evidence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm9030623

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 553

Metadata

Authors
Pang, J., Wang, M. X., Ang, I. Y. H., Tan, S. H. X., Lewis, R. F., Chen, J. I.-P., Gutierrez, R. A., Gwee, S. X. W., Chua, P. E. Y., Yang, Q., Ng, X. Y., Yap, R. K. S., Tan, H. Y., Teo, Y. Y., Tan, C. C., Cook, A. R., Yap, J. C.-H., & Hsu, L. Y.
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2020-02-26
Volume
9
Issue
3
Pages
623
ISSN
2077-0383 (ISSN-L)
OpenAlex
W3008644093
Cited by
553
References
53
FWCI
7.43
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review. https://app.cochat.ai/papers/10.3390/jcm9030623
The paper
Pang, J., Wang, M. X., Ang, I. Y. H., Tan, S. H. X., Lewis, R. F., Chen, J. I.-P., Gutierrez, R. A., Gwee, S. X. W., Chua, P. E. Y., Yang, Q., Ng, X. Y., Yap, R. K. S., Tan, H. Y., Teo, Y. Y., Tan, C. C., Cook, A. R., Yap, J. C.-H., & Hsu, L. Y. (2020). Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review. Journal of Clinical Medicine. https://doi.org/10.3390/jcm9030623

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.